Latest Headlines

Latest Headlines

Novartis reshuffles its $9B R&D operation to save $1B a year

Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines.

Case Western, Merck team spotlights vaccine response predictors

Using a "systems vaccinology" approach, researchers at Case Western Reserve University School of Medicine and Merck Research Laboratories have published findings that suggest a new way to predict and enhance vaccine effectiveness, in particular with hepatitis B vaccination.

Codiak piles on more venture cash, amassing $92M for exosome R&D

Startup Codiak BioSciences got off the ground in November with ambitious plans to turn exosomes into cancer therapies and venture commitments totaling more than $80 million. Now the Cambridge, MA, company has boosted its funding total to $92 million, extending its runway as it works through early-stage R&D.

Combining light-activated and chemical treatments, new nanoparticles are more effective against tumors

A team of researchers in Massachusetts is developing a two-in-one nanoparticle that delivers both a photodynamic therapy and a molecular therapy to treat highly resistant tumors--such as those associated with pancreatic cancer--with decreased toxicity.

UNC team delivers cancer drugs wrapped in exosomes to cut doses

Researchers at the University of North Carolina have developed a method of drug delivery using exosomes to protect cancer drugs in the body before they reach their target, effectively cutting the necessary dose.

Galapagos' bowel drug misses the mark in Phase II

Belgian biotech Galapagos is shutting down an ulcerative colitis program after its top prospect failed to make a difference in a Phase II trial, putting off plans for late-stage development as the company weighs whether to move forward in another disease.

Startup Co-D aims to resuscitate failed BMS drug using polymeric micelle drug delivery

University of Wisconsin-Madison spinout Co-D is deploying its polymeric micelle drug delivery platform with the aim of commercializing a failed Bristol-Myers Squibb cancer drug. So-called Triolimus boasts FDA's orphan drug designation to treat the rare blood vessel cancer angiosarcoma, a milestone that will accelerate its path to FDA approval (or rejection).

Zika outbreak triggers R&D attention from pharma, governments

As the Zika virus continues to grab headlines and its spread threatens, governments and industry are urgently committing resources and analyzing vaccine development options.

Panasonic, Kyoto University unveil radar-based remote vital sign sensor

Kyoto University and Panasonic have revealed a novel vital-sign-sensing technology that's based on radar. This enables the system to remotely detect heart rate and heartbeat interval without any sensors being placed on the patient's body. The accuracy of the system is on par with electrocardiographs.

Cedars-Sinai to test Fitbit activity trackers in cancer clinical trial

Cedars-Sinai is planning to trial the use of Fitbit Charge HR activity trackers to gauge the suitability of cancer patients for certain treatments, MobiHealthNews reports.